NCT06996730
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Phase: Phase 2/3
Role: Lead Sponsor
Start: Jan 15, 2026
Completion: Jun 1, 2030